Dr. Balar on Mature Clinical Results of KEYNOTE-052 in Urothelial Cancer OncLive 1:57 7 years ago 281 Далее Скачать
Results for First-Line Pembrolizumab in Advanced Urothelial Carcinoma Targeted Oncology 1:58 7 years ago 92 Далее Скачать
How effective is pembrolizumab in cisplatin-ineligible bladder cancer? Results from KEYNOTE-052 VJOncology 1:23 7 years ago 306 Далее Скачать
Dr. Balar on Combinations with Pembrolizumab for Urothelial Cancer OncLive 0:47 7 years ago 31 Далее Скачать
Dr. Balar on IMvigor 210 Results for Metastatic Urothelial Carcinoma OncLive 1:25 8 years ago 362 Далее Скачать
Dr. Petrylak on the KEYNOTE-045 Trial for Urothelial Carcinoma OncLive 0:57 7 years ago 62 Далее Скачать
Dr. Balar on Biomarkers of Immunotherapy Response in Bladder Cancer OncLive 0:54 5 years ago 85 Далее Скачать
KEYNOTE-057 update: pembrolizumab for high-risk NMIBC patients VJOncology 3:16 5 years ago 256 Далее Скачать
IMvigor 210 Results in Metastatic Urothelial Carcinoma Targeted Oncology 0:16 8 years ago 232 Далее Скачать
Dr. Balar on the Approval of Pembrolizumab for Bladder Cancer OncLive 0:51 7 years ago 96 Далее Скачать
Results of a First-Line Study of Pembrolizumab in Advanced Urothelial Cancer Targeted Oncology 2:15 8 years ago 123 Далее Скачать
Two-Year Follow-Up Results from KEYNOTE-045 Study in Urothelial Carcinoma Targeted Oncology 1:54 6 years ago 76 Далее Скачать
KEYNOTE-045 – pembrolizumab as second-line treatment in urothelial carcinoma VJOncology 1:09 7 years ago 205 Далее Скачать
Copy of Dr. Balar on Next Steps of the KEYNOTE-057 Trial in NMIBC OncLive 0:45 5 years ago 14 Далее Скачать
